You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

CDK 4/6 Inhibitors in Breast Cancer: Expert Perspectives on New Data

  • Authors: Javier Cortes, MD, PhD; Fabrice André, MD, PhD
  • CPD Released: 12/20/2018
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 12/20/2019
Start Activity


Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US healthcare professionals, specifically oncologists involved in the treatment of patients with breast cancer.

The goal of this activity is to improve physicians' understanding regarding the use of cyclin-dependent kinase (CDK) 4/6 inhibitors in breast cancer.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Latest efficacy data supporting use of CDK 4/6 inhibitors for the treatment of hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer (MBC) and its clinical implications
    • Safety and tolerability data for CDK 4/6 inhibitors for the treatment of HR+, HER2- MBC


Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.


Faculty

  • Javier Cortés, MD, PhD

    Head
    Breast Cancer Program
    Oncology Department
    Ramon y Cajal University Hospital
    Madrid, Spain

    Disclosures

    Disclosure: Javier Cortes, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Biothera Pharmaceuticals, Inc.; Celgene Corporation; Cellestia Biotech; Eisai Inc.; Merus; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche; Seattle Genetics, Inc.

  • Fabrice André

    Professor
    Chairman Inserm Unit U981
    Institut Gustave Roussy
    Villejuif, France

    Disclosures

    Disclosure: Fabrice André, MD, PhD, has disclosed the following relevant financial relationships:
    Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche

Steering Committee

  • Nadia Harbeck, MD, PhD (Chair)

    Professor
    Breast Center
    Department of Obstetrics and Gynecology
    University of Munich (LMU)
    Munich, Germany

    Disclosures

    Disclosure: Nadia Harbeck, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer Inc.
    Served as a speaker or a member of a speakers bureau for: Novartis Pharmaceuticals Corporation; Pfizer Inc.

  • Javier Cortés, MD, PhD

    Head
    Breast Cancer and Gynecological Tumours
    Ramón y Cajal University Hospital
    Oncology Department, Madrid
    Clinical Investigator
    Breast Cancer Research Program
    Vall d’Hebron Institute of Oncology
    Barcelona, Spain

    Disclosures

    Disclosure: Javier Cortés, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Biothera Pharmaceuticals, Inc.; Celgene Corporation; Cellestia Biotech; Roche
    Served as a speaker or a member of a speakers bureau for: Celgene Corporation; Eisai Co., Ltd; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche

  • Angelo Di Leo, MD, PhD

    Head, Medical Oncology Unit
    Chair, Oncology Department
    "Sandro Pitigliani" Medical Oncology Unit - Department of Oncology
    Hospital of Prato
    Istituto Toscano Tumori
    Prato, Italy

    Disclosures

    Disclosure: Angelo Di Leo, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bayer HealthCare Corporation; Celgene Corporation; Eisai Co., Ltd; Genomic Health; Ipsen; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Pierre Fabre; Roche

  • Stephen R.D. Johnston, MA, FRCP, PhD

    Professor of Breast Cancer Medicine
    Royal Marsden Hospital
    London, United Kingdom

    Disclosures

    Disclosure: Stephen R.D. Johnston, MA, FRCP, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Puma Biotechnology; Roche
    Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; GlaxoSmithKline; Pfizer Inc.; Puma Biotechnology
    Received grants for clinical research from: GlaxoSmithKline; Pfizer Inc.

  • Xavier Pivot, MD, PhD

    Professor
    J Minjoz University Hospital
    Besancon, France

    Disclosures

    Disclosure: Xavier Pivot, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Amgen Inc.; Novartis Pharmaceuticals Corporation; Roche
    Served as a speaker or a member of a speaker's bureau for: Eisai Co., Ltd; Novartis Pharmaceuticals Corporation; Roche

  • Sunil Verma, MD, MSEd, FRCPC

    Professor
    Department of Oncology
    Cumming School of Medicine
    University of Calgary
    Calgary, Alberta, Canada

    Disclosures

    Disclosure: Sunil Verma, MD, MSEd, FRCPC, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche

Content Reviewer

  • Nafeez Zawahir, MD

    CME Clinical Director

    Disclosures

    Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Editor

  • Deborah Middleton, MS

    Scientific Director, WebMD Global, LLC

    Disclosures

    Disclosure: Deborah Middleton, MS, has disclosed no relevant financial relationships.

  • Anne M. Sendaydiego, PharmD

    Scientific Director, WebMD Global, LLC

    Disclosures

    Disclosure: Anne M. Sendaydiego, PharmD, has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.25 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

CDK 4/6 Inhibitors in Breast Cancer: Expert Perspectives on New Data

Authors: Javier Cortes, MD, PhD; Fabrice André, MD, PhDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CPD Released: 12/20/2018

Valid for credit through: 12/20/2019

processing....